132 related articles for article (PubMed ID: 38537440)
1. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo.
Chiu SC; Huang SY; Chen SP; Su CC; Chiu TL; Pang CY
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):315-22. PubMed ID: 24042854
[TBL] [Abstract][Full Text] [Related]
6. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA enhances susceptibility of non-small cell lung cancer cells to NK cell-mediated lysis by up-regulating ULBP1 and DR5.
Sun Y; Gong C; Ni Z; Hu D; Ng W; Zhu X; Wang L; Si G; Yan X; Zhao C; Yao C; Zhu S
J Leukoc Biol; 2021 Aug; 110(2):315-325. PubMed ID: 33909909
[TBL] [Abstract][Full Text] [Related]
8. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
9. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA ameliorates cognitive deficits by inhibiting endoplasmic reticulum stress-induced apoptosis in APP/PS1 transgenic mice.
He Y; Ruganzu JB; Lin C; Ding B; Zheng Q; Wu X; Ma R; Liu Q; Wang Y; Jin H; Qian Y; Peng X; Ji S; Zhang L; Yang W; Lei X
Neurochem Int; 2020 Feb; 133():104610. PubMed ID: 31778727
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA inhibits gastric carcinoma AGS cells through increasing p-p38, p-JNK and p53 but reducing p-ERK, CDC2 and cyclin B1 expression.
Su CC
Anticancer Res; 2014 Dec; 34(12):7097-110. PubMed ID: 25503137
[TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
14. Tanshinone IIA inhibits BT-20 human breast cancer cell proliferation through increasing caspase 12, GADD153 and phospho-p38 protein expression.
Yan MY; Chien SY; Kuo SJ; Chen DR; Su CC
Int J Mol Med; 2012 May; 29(5):855-63. PubMed ID: 22322382
[TBL] [Abstract][Full Text] [Related]
15. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
[TBL] [Abstract][Full Text] [Related]
17. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer.
Zhang YF; Zhang ZH; Li MY; Wang JY; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Zuo HX; Jin HL; Ma J; Jin X
Phytomedicine; 2021 Jan; 81():153425. PubMed ID: 33310309
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells.
Jiang Y; Bi Y; Zhou L; Zheng S; Jian T; Chen J
BMC Complement Med Ther; 2024 Jan; 24(1):68. PubMed ID: 38297301
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway.
Liu H; Liu C; Wang M; Sun D; Zhu P; Zhang P; Tan X; Shi G
Sci Rep; 2021 Sep; 11(1):19268. PubMed ID: 34588580
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]